The company achieved record net sales of $133.5 million in Q3 2025, representing 38% year-over-year growth, demonstrating strong market momentum. Glaukos maintains a strong balance sheet with significant institutional ownership and absence of debt, positioning it for sustained expansion across its glaucoma, corneal disorder, and emerging retinal disease portfolios.
Cyborg Score Rationale
The company is experiencing exceptional growth with record Q3 2025 net sales of $133.5M (+38% YoY) and U.S. glaucoma sales of $80.8M (+57% YoY). Strong financial health and innovative product pipeline support bullish outlook, though valuation metrics suggest moderate premium pricing.
Top Insights
Company raised 2025 guidance to $490-495M and introduced 2026 guidance of $600-620M in net sales, indicating confidence in continued acceleration
Flagship iStent and iStent infinite products treat mild-to-moderate and therapy-resistant glaucoma, complemented by iDose TR intracameral delivery technology
Three primary commercialized micro-scale surgical device products designed to treat glaucoma represent market-leading MIGS portfolio
Strong liquidity with current ratio of 5.2 and debt-to-equity of 0.14 reflects conservative financial management
Named Competitors
JWAK — Glaucoma management platforms
Glaucoma Solutions — Comprehensive glaucoma care portfolio
LenSx — Femtosecond laser and ophthalmic platforms
Recent Developments
(September 2025) Record Q3 2025 net sales of $133.5M with 38% YoY growth and 45% growth in glaucoma segment
(December 2025) Participated in Citi Annual Global Healthcare Conference
(January 2026) Recognized on America's Greenest Companies 2026 by Newsweek
Open the full interactive Glaukos Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.